KR-33494

Research use only, not for human use.

A potent inhibitor for Fas-mediated cell death, FAF1, inhibits ischemic cell death.

A potent inhibitor for Fas-mediated cell death, FAF1, inhibits ischemic cell death.

——

Body weight changes of both sexes are not related to KR-33493 in all doses. In rats administrated KR-33493 for 4 weeks, no test article-related changes in any treated groups of either sex are found in hematology, serum biochemistry, and urinalysis. In dogs administrated KR-33493 for 2 weeks, red blood cell count (RBC) value in males is significantly higher at the 1000 mg/kg/day dose than that of the control group (i.e., 6.96±0.323 vs. 6.12±0.418). However, the change of RBC is recovered after the end of the administration period. The dose-normalized AUClast is not significantly different between the groups, suggesting that KR-33493 is governed by linear kinetics.

KR 33494 | KR33494

Apoptosis

Fas Receptor

Fas Receptor

——

——

1021497-97-1

460.3442

C20H18BrN3O3S

>98% (HPLC)

DMSO: ≥ 31 mg/mL

O=C(C1=NN(CCC2=CC=CC=C2)C=C1NC(CSC3=CC=C(Br)C=C3)=O)O

1H-Pyrazole-3-carboxylic acid, 4-[[2-[(4-bromophenyl)thio]acetyl]amino]-1-(2-phenylethyl)-

(-20℃)

With Ice Pack

≥ 2 years